{ "items": [ "\n\n
\n \n\n \n \n \n \n FMRIB\n \n \n \n \n NDCN\n \n \n\n \n\n\n
\n \n \n \n\n \n \n\n \n\n \n \n \n \n CPSD\n \n \n\n \n\n\n
\n \n \n \nCPSD runs several research studies looking into the causes, investigation, and management of large artery atherosclerosis, carotid stenosis, vertebral artery disease and intracranial atherosclerosis.
\n \n\n \n \n\n \n\n \n \n \n \n CPSD\n \n \n\n \n\n\n
\n \n \n \nThe Oxford Project to Investigate Memory and Ageing (OPTIMA) started in 1988 and the last LEAD participants were seen in March 2015. We are no longer recruiting to any of the cohorts. However, we are currently creating the OPTIMA Legacy Resource from which data collected from the OPTIMA cohorts is available and samples are biobanked and available. Brain tissue is available as part of the Brains For Dementia Research (BDR) collection.
\n \n\n \n \n\n \n\n \n \n \n \n CPSD\n \n \n\n \n\n\n
\n \n \n \nThe Oxford Vascular Study (OxVasc) investigates vascular diseases (e.g. strokes, heart attacks) in patients registered with eight general practices in Oxfordshire. We run a rapid-access clinic for patients with suspected Transient Ischaemic Attacks (TIAs) or minor strokes.\r\n\r\nAll OxVasc clinics held in the Wolfson Centre for the Prevention of Stroke and Dementia follow Oxford University Hospitals NHS Foundation Trust infection control guidelines.
\n \n\n \n \n\n \n\n \n \n \n \n FMRIB\n \n \n\n \n\n\n
\n \n \n \nBeliefs shape our perception of pain. Using non-invasive magnetic resonance imaging in humans, we investigate how beliefs are generated, maintained and revised in the brain and how they influence pain perception.
\n \n\n \n \n\n \n\n \n \n \n \n DCN\n \n \n \n \n NDCN\n \n \n\n \n\n\n
\n \n \n \nOur goal is to develop ways of accurately measuring neurological disorders such as Parkinson\u2019s disease and Progressive Supranuclear Palsy.
\n \n\n \n \n\n \n\n \n \n \n \n DCN\n \n \n\n \n\n\n
\n \n \n \nWe study why certain neuronal populations are vulnerable to neurodegeneration in Parkinson\u2019s disease brain and whether pathological changes seen in the peripheral tissues mirror or precede what is ultimately seen in the brain, and how this can be used to develop biomarkers.
\n \n\n \n \n\n \n\n \n \n \n \n FMRIB\n \n \n \n \n NDCN\n \n \n\n \n\n\n
\n \n \n \nOur research aims to understand the characteristics of individual brain tumours, combining cutting edge brain imaging, molecular neuropathology and neurosurgical techniques to develop personalized approaches for first-line cancer surgery.
\n \n\n \n \n\n \n\n \n \n \n \n DCN\n \n \n\n \n\n\n
\n \n \n \nThis cross-disciplinary research group links neuropathology, endocrinology and molecular genetics to explore how the genetics and epigenetics of pituitary tumours influences clinical characteristics and to identify targets for therapeutic intervention.
\n \n\n \n \n\n \n\n \n \n \n \n FMRIB\n \n \n\n \n\n\n
\n \n \n \nIn this research area novel methodological approaches are developed for working with extremely large databases of MR images, or images and genetics, and the complex statistics required in neuroimaging.
\n \n\n \n \n\n \n\n \n \n \n \n FMRIB\n \n \n\n \n\n\n
\n \n \n \n\n \n \n\n \n\n \n \n \n \n NDCN\n \n \n \n \n NLO\n \n \n\n \n\n\n
\n \n \n \n\n \n \n\n \n\n \n \n \n \n FMRIB\n \n \n \n \n NDA\n \n \n\n \n\n\n
\n \n \n \nThe Pain Analgesia/Anaesthesia Imaging Neuroscience group is a multidisciplinary team of scientists and clinicians. We research how the human central nervous system generates and modulates painful experiences in acute and chronic settings.
\n \n\n \n \n\n \n\n \n \n \n \n FMRIB\n \n \n \n \n NDCN\n \n \n\n \n\n\n
\n \n \n \nOur group uses multimodal approaches to understand physiological changes in the brain, both in the context of learning novel motor skills and in a range of neurological conditions. To do this we use MR Spectroscopy, MR Imaging, Magnetoencephalography (MEG) and Non-Invasive Brain Stimulation.\r\n\r\nUltimately we hope to understand more about how the brain adapts to new challenges, so that we can develop new adjunctive therapies for recovery.
\n \n\n \n \n\n \n\n \n \n \n \n DCN\n \n \n\n \n\n\n
\n \n \n \nOur group uses computer simulations and mathematical analyses to understand the information processing and activity dynamics of brain networks underlying decision making. We use these models to investigate how neural circuits work in the healthy state, how their dynamics deteriorate in neurological disorders, and how their dynamics and information processing may be best restored by treatments.
\n \n\n \n \n\n \n\n \n \n \n \n DCN\n \n \n \n \n NDCN\n \n \n\n \n\n\n
\n \n \n \nResearch, diagnostic and testing service of autoantibodies associated with neurological diseases.
\n \n\n \n \n\n \n\n \n \n \n \n NDA\n \n \n \n \n NDCN\n \n \n\n \n\n\n
\n \n \n \n\n \n \n\n \n\n \n \n \n \n NDA\n \n \n\n \n\n\n
\n \n \n \n\n \n \n\n \n\n \n \n \n \n DCN\n \n \n\n \n\n\n
\n \n \n \nWe are a forward-looking dynamic group interested in all aspects of clinical and experimental epileptology with an emphasis on clinically relevant research. The Group draws together all relevant disciplines across Oxford University Hospitals and the University of Oxford.
\n \n\n \n \n\n \n\n \n \n \n \n DCN\n \n \n\n \n\n\n
\n \n \n \nOur aim is to understand fundamental biological processes that could inform the development of targeted therapies and innovative biomarkers in neurodegenerative and neurogenetic disorders.
\n \n\n \n \n